Liječenje multiple skleroze lijekom okrelizumab – retrospektivna 1,5-godišnja analiza u Klinici za neurologiju Kliničkog bolničkog centra Sestre milosrdnice u Zagrebu
| العنوان: | Liječenje multiple skleroze lijekom okrelizumab – retrospektivna 1,5-godišnja analiza u Klinici za neurologiju Kliničkog bolničkog centra Sestre milosrdnice u Zagrebu |
|---|---|
| المؤلفون: | NEVENA GRBIĆ, MILJENKA-JELENA JURAŠIĆ, LUCIJA ZADRO MATOVINA, IRIS ZAVORERO, IVANA VINSKI, VANJA BAŠIĆ KES |
| المصدر: | Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske Volume 74 Issue 3 |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | multipla skleroza, okrelizumab, liječenje, iskustva, multiple sclerosis, ocrelizumab, treatment, experience |
| الوصف: | U odnosu na važnost T limfocita u patogenezi multiple skleroze (MS) sve se više otkriva i značenje B limfocita u samoj patogenezi bolesti. Okrelizumab (Ocrevus®, Roche, Njemačka) je monoklonsko protutijelo koje ciljano djeluje na B stanice koje sadrže CD20 antigen. Brojna ispitivanja pokazala su djelotvornost okrelizumaba u liječenju relapsno remitentne multiple skleroze (RRMS) i primarno progresivne multiple skleroze (PPMS). Ranija klinička ispitivanja su pokazala da primjena okrelizumaba suprimira relapse, progresiju bolesti te supkliničku aktivnost bolesti utvrđenu magnetskom rezonancom (MR). Na Klinici za neurologiju Kliničkog bolničkog centra Sestre milosrdnice retrospektivno smo analizirali bolesnike kod kojih je bilo indicirano liječenje okrelizumabom. Ukupno je lijek primijenjen kod 36 bolesnika s RRMS-om i 13 bolesnika s PPMS-om. Cilj je bio prikazati populaciju bolesnika kod kojih je primijenjen lijek, njihove nuspojave te klinički ishod nakon primjene lijeka uz usporedbu navedenih podataka s dosadašnjim saznanjima o lijeku. Našom analizom u skupini s RRMSom kod 47 % bolesnika primijenjen je drugi ciklus liječenja, a kod 8 % bolesnika i treći ciklus liječenja. Od navedenih bolesnika 94 % nije pokazalo kliničku progresiju bolesti. Što se nuspojava tiče u skupini bolesnika s RRMS-om 11 % je imalo nuspojave, a u skupini bolesnika s PPMS-om 23 % . Najčešće nuspojave bile su reakcija na infuziju i smanjenje broja limfocita (za sada još uvijek na granici s donjom graničnom vrijednosti). Analizom naših bolesnika potvrđeni su prethodni zaključci kliničkih ispitivanja. Lijek se pokazao sigurnim za primjenu uz malu učestalost nuspojava. Ipak, potreban je veći broj bolesnika za daljnju analizu što planiramo učiniti u budućim analizama. Considering importance of T lymphocytes in the pathogenesis of multiple sclerosis, the importance of B lymphocytes in the pathogenesis of the disease is increasingly revealed. Ocrelizumab (Ocrevus®, Roche, Germany) is a monoclonal antibody that targets B cells expressing CD20 antigen. Numerous studies have demonstrated the effi cacy of ocrelizumab in the treatment of relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Previous clinical trials have shown that ocrelizumab administration suppresses relapses, disease progression and subclinical disease activity as determined by the method of magnetic resonance imaging. We retrospectively analyzed patients at the Department of Neurology, Sestre milosrdnice University Hospital Centre. Ocrelizumab was administered to 36 patients with RRMS and 13 patients with PPMS. The aim was to present the population of patients administered the drug, their side effects and clinical outcome after administration of the drug, comparing the above data with current knowledge on the drug. In our RRMS group analysis, 47% of patients were administered second treatment cycle and 8% were administered third cycle; 94% of these patients showed no clinical progression of the disease. In the groups of RRMS and PPMS patients, adverse events were recorded in 11% and 23% of patients, respectively. The most common side effects were response to infusion and decrease in lymphocyte count (still at the border of the lower reference value). The analysis of our patients confi rmed previous fi ndings of clinical studies. The drug has been proven to be safe to administer with a low incidence of side effects. Nevertheless, more patients are needed for further and detailed analysis, motivating us for further monitoring and publication of a new analysis in the future. |
| وصف الملف: | application/pdf |
| اللغة: | Croatian |
| تدمد: | 1330-0164 1848-8897 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::8d01c357dd5a2d474ea7bff196a26b1b https://www.bib.irb.hr/1171729 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.dedup.wf.001..8d01c357dd5a2d474ea7bff196a26b1b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13300164 18488897 |
|---|